Page 194 - DUOKOPT BIBLIOBOOK

DUOKOPT - bibliography book - CONFIDENTIAL - document for exclusive use by personnel of Laboratoires Théa – DO NOT DISTRIBUTE
®

After 8 weeks of treatment:
144 (81.8%) patients were either satisfied or very satisfied with the PF dorzolamide-timolol formulation and
the ophthalmologists for 155 (88.1%) of the patients.

CONCLUSIONS: In newly diagnosed glaucoma or OHT patients, PF dorzolamide-timolol does not increase
eye discomfort. Over 80% of patients and ophthalmologists are satisfied with the PF dorzolamide–timolol
formulation. This could contribute to improved quality of life during the course of treatment.

KEY MESSAGES

X PF DTFC does not increase eye discomfort.

X PF formulation may constitute an advantageous treatment alternative that provides a
better tolerability for patients sensitive to preservative or for whom the utilization of PF
formulation is otherwise advisable.

STRENGTHS

X 8 week prospective study evaluating PF DTFC in newly diagnosed patients.
X Patients and ophthalmologists are satisfied with the PF DTFC formulation.

X The study results are generalizable to the Canadian target population.
X The use of the PF formulation therefore did not increase eye discomfort, which may have
been an important factor contributing to high compliance with therapy. This could result
in optimization of long-term treatment effectiveness

WEAKNESSES

X The study has not included a comparative group.

MARKETING CLAIM

X In newly diagnosed patients, PF Dorzolamide-Timolol combination does not increase
eye discomfort and contributes to both high patients and ophtalmogists satisfaction.

194